🚀 VC round data is live in beta, check it out!
Bausch Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bausch Health and similar public comparables like Stoke Therapeutics, PegBio, AddLife, Mehow Innovative and more.
Bausch Health Overview
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Founded
1994
HQ
Employees
20.3K
Website
Financials (LTM)
EV
$22B
Bausch Health Financials
Bausch Health reported last 12-month revenue of $10B and EBITDA of $4B.
In the same LTM period, Bausch Health generated $7B in gross profit, $4B in EBITDA, and $1B in net income.
Revenue (LTM)
Bausch Health P&L
In the most recent fiscal year, Bausch Health reported revenue of $10B and EBITDA of $4B.
Bausch Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10B | XXX | $10B | XXX | XXX | XXX |
| Gross Profit | $7B | XXX | $7B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $20B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bausch Health Stock Performance
Bausch Health has current market cap of $2B, and enterprise value of $22B.
Market Cap Evolution
Bausch Health's stock price is $5.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22B | $2B | 1.8% | XXX | XXX | XXX | $3.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBausch Health Valuation Multiples
Bausch Health trades at 2.1x EV/Revenue multiple, and 6.0x EV/EBITDA.
EV / Revenue (LTM)
Bausch Health Financial Valuation Multiples
As of April 18, 2026, Bausch Health has market cap of $2B and EV of $22B.
Equity research analysts estimate Bausch Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bausch Health has a P/E ratio of 1.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $22B | XXX | $22B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | 6.5x | XXX | 6.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| P/E | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| EV/FCF | 33.2x | XXX | 21.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bausch Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bausch Health Margins & Growth Rates
Bausch Health's revenue in the last 12 month grew by 3%.
Bausch Health's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Bausch Health's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bausch Health's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bausch Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bausch Health Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bausch Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Stoke Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PegBio | XXX | XXX | XXX | XXX | XXX | XXX |
| AddLife | XXX | XXX | XXX | XXX | XXX | XXX |
| Mehow Innovative | XXX | XXX | XXX | XXX | XXX | XXX |
| Yifan Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bausch Health M&A Activity
Bausch Health acquired XXX companies to date.
Last acquisition by Bausch Health was on XXXXXXXX, XXXXX. Bausch Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bausch Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBausch Health Investment Activity
Bausch Health invested in XXX companies to date.
Bausch Health made its latest investment on XXXXXXXX, XXXXX. Bausch Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bausch Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bausch Health
| When was Bausch Health founded? | Bausch Health was founded in 1994. |
| Where is Bausch Health headquartered? | Bausch Health is headquartered in Canada. |
| How many employees does Bausch Health have? | As of today, Bausch Health has over 20K employees. |
| Who is the CEO of Bausch Health? | Bausch Health's CEO is Thomas J. Appio. |
| Is Bausch Health publicly listed? | Yes, Bausch Health is a public company listed on NYSE. |
| What is the stock symbol of Bausch Health? | Bausch Health trades under BHC ticker. |
| When did Bausch Health go public? | Bausch Health went public in 1994. |
| Who are competitors of Bausch Health? | Bausch Health main competitors are Stoke Therapeutics, PegBio, AddLife, Mehow Innovative. |
| What is the current market cap of Bausch Health? | Bausch Health's current market cap is $2B. |
| What is the current revenue of Bausch Health? | Bausch Health's last 12 months revenue is $10B. |
| What is the current revenue growth of Bausch Health? | Bausch Health revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Bausch Health? | Current revenue multiple of Bausch Health is 2.1x. |
| Is Bausch Health profitable? | Yes, Bausch Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bausch Health? | Bausch Health's last 12 months EBITDA is $4B. |
| What is Bausch Health's EBITDA margin? | Bausch Health's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Bausch Health? | Current EBITDA multiple of Bausch Health is 6.0x. |
| What is the current FCF of Bausch Health? | Bausch Health's last 12 months FCF is $654M. |
| What is Bausch Health's FCF margin? | Bausch Health's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Bausch Health? | Current FCF multiple of Bausch Health is 33.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.